

*SSG working group meeting, joint session November 29, 2010*

Number of participants: 80

Place: DGI-byens hotel, DGI-byen, Copenhagen

One of our two chairmen, Otte Brosjö, made a welcome address to all participants, more than ever in spite of the newly introduced participant fee.

Clement Trovik reported on the present status of the SSG central registry, which is improving but still is lacking data especially from some centres.

Mikael Eriksson reported on the SSG participation in two global registry based studies, LIVESTRONG and the Vancouver-project. For details, see minutes from the board meeting November 28!

Sigbjørn Smeland reported on the status of past, present and potential future osteosarcoma protocols. EURAMOS-1 will be closed for inclusion in May 2011. Regarding future planning and organization, see minutes from the board meeting and oncology subcommittee meeting

Mikael Skorpil discussed suggestions in the radiology subcommittee regarding changed policy in imaging of bone sarcomas, using PET scan instead of conventional bone scanning. Advantages and hazards with this strategy were discussed, and the subcommittee will take these views into consideration.

Nina Jebsen presented the status of her thesis "Effect of surgery and radiotherapy in soft tissue sarcoma of the extremities and trunk wall". The results from SSG XIII has recently been published.

Kirsten Sundby Hall reported the present situation for the adjuvant SSG XX protocol for soft tissue sarcomas of the extremities and trunk wall. Inclusion is as expected, but rather marked discrepancy in inclusion rate between different centres is consistently noted, which is hard to explain. One problem is the evaluation of radiation induced side effects, see minutes from the oncology subcommittee meeting.

In the SSG matters section a brief report of the board meeting was given by Kirsten Sundby Hall. The members of the up-coming EURAMOS-groups were decided as suggested by the board, including also Catherine Rechnitzer in the strategy group (Sigbjørn Smeland has not been available for new osteosarcoma projects due to other work tasks). For more details, see minutes from the board meeting and oncology subcommittee meeting.

Lund December 20

Mikael Eriksson